16198-01-9

Usage

Uses

Used in Pharmaceutical Applications:
(+)-Catechin-pentaacetate is used as a pharmaceutical agent for its potential health benefits, including antioxidant and anti-inflammatory effects. Its ability to protect cells from oxidative damage and its anti-aging properties make it a promising candidate for the development of new drugs for the treatment of various diseases.
Used in Cosmetic Applications:
In the cosmetic industry, (+)-Catechin-pentaacetate is used as an active ingredient for its cell-protecting and anti-aging properties. Its antioxidant capabilities contribute to the development of products aimed at reducing the signs of aging and promoting skin health.
Used in Antioxidant Formulations:
(+)-Catechin-pentaacetate is utilized as an antioxidant in various formulations, capitalizing on its ability to neutralize free radicals and protect against oxidative stress. This application spans across different industries, including food and beverage, where it can extend shelf life and maintain product quality.
Used in Research and Development:
In the scientific community, (+)-Catechin-pentaacetate serves as a subject of research for exploring its potential applications in medicine and other fields. Ongoing studies aim to uncover its full range of benefits and optimize its use in various products and treatments.

Upstream product

• 127-09-3 sodium acetate 
• 108-24-7 acetic anhydride 
• 154-23-4 catechin 
• 6685-67-2 2-(3,4-diacetoxyphenyl)-4-oxochroman-3,5,7-triyl triacetate 
• 623-05-2 (4-hydroxyphenyl)methanol 
• 154-23-4 catechin 
• 490-46-0 (2R,3R)-2-(3,4-dihydroxyphenyl)-3,4-dihydro-1[2H]-benzopyran-3,5,7-triol 
• 154-23-4 (-)-catechin 
• 7295-85-4 catechin 
• 6685-67-2 (+/-)-taxifolin pentaacetate 
• 67-56-1 methanol 
• 65052-92-8 (+/-)-2,3-trans-3,4-trans-4-hydroxy-3,5,7,3',4'-pentaacetoxyflavan 
• 154-23-4 (+/-)-epicatechin 
• 132400-73-8 (+/-)-catechin 3,7,3',4'-tetraacetate 

Downstream Products

• 116935-88-7 acetate of (+)-catechin 
• 51126-02-4 4β-bromopenta-O-acetyl-(+)-catechin 
• 154-23-4 catechin 
• 1209469-08-8 (+)-3,5,7,3'-tetra-O-acetylcatechin 
• 1209469-09-9 (+)-3,5,7,4'-tetra-O-acetylcatechin 
• 1209469-13-5 (+)-3-O-acetylcatechin 3'-O-β-D-glucoside 
• 1209469-11-3 3,5,7,3',2'',3'',4'',6''-octa-O-acetyl-(+)-catechin 4'-O-β-D-glucoside 
• 1209469-10-2 3,7,3',4',2'',3'',4'',6''-octa-O-acetyl-(+)-catechin 5-O-β-D-glucoside 
• 1209469-12-4 3,5,7,4',2'',3'',4'',6''-octa-O-acetyl-(+)-catechin 3'-O-β-D-glucoside 
• 105330-52-7 (+)-catechin 4'-O-β-D-glucopyranoside 
• 105330-51-6 (+)-catechin 3'-O-β-D-glucopyranoside 
• 88126-53-8 (+)-epicatechin 5-O-β-D-glucopyranoside 
• 51126-02-4 4β-bromopenta-O-acetyl-(-)-epicatechin 
• 548756-51-0 3,7,3',4'-tetraacetyl (-)-epicatechin 

Relevant academic research and scientific papers

Mechanism of biochemical action of substituted 4-methylbenzopyran-2-ones. Part 10: Identification of inhibitors for the liver microsomal acetoxycoumarin: Protein transacetylase

The quantitative structure-activity relationship (QSAR) studies conducted by us earlier revealed the cardinal role of the pyran ring carbonyl group in the acetoxy polyphenolic compounds for the acetoxy polyphenol:protein transacetylase (TAase) activity. H

Catechin Derivatives as Inhibitor of COVID-19 Main Protease (Mpro): Molecular Docking Studies Unveil an Opportunity Against CORONA

Background: A newly emergent strain of coronavirus (COVID-19) has affected almost the whole of the world’s population. Currently, there is no specific vaccine or drug against COVID-19. Xu et al. (2020) built a homolog model of SARS-CoV-2 Mpro b

Benzophenone Glucosides and B-Type Proanthocyanidin Dimers from Zambian Cassia abbreviata and Their Trypanocidal Activities

Two benzophenone glucosides (1 and 2), five flavan-3-ol dimers (5–9), and 17 known compounds (3, 4, and 10–24) were identified from the bark extract of Cassia abbreviata. The chemical structures display two points of interest. First, as an unusual charact

Novel 3C-like protease inhibitor as well as preparation method and application thereof

The invention provides a novel 3C-like protease inhibitor which is 3 ", 4" - O - diacetyl -epicatechin trans-caffeic acid ester with a specific structure. The invention further provides a preparation method and application of the 3C-like protease inhibitor. The invention has the advantages that the compound 3 ", 4" - O - diacetyl - epicatechin trans-caffeic acid ester is designed and synthesized based on the structure of epicatechin; even when the concentration is low, the activity of 3C-like protease in the novel coronavirus can be obviously inhibited. The compounds can be used as 3C-like protease inhibitors and are used for preparing anti-novel coronavirus SARS-CoV - 2 infection drugs.

Preparation method and application of hydroxyl cinnamyl ester type catechin

The invention relates to a preparation method and application of hydroxyl cinnamyl ester type catechins. The hydroxyl cinnamyl ester type catechins comprise four catechins which are respectively namedas epicatechin trans-coumarate, epicatechin trans-caffeic acid ester, epigallocatechin trans-coumarate and epigallocatechin trans-caffeic acid ester. The hydroxyl cinnamyl ester type catechins are prepared by the following steps: carrying out four steps of full acetylation on epicatechin and epigallocatechin, removal of acetyl on phenolic hydroxyl, silanizing of phenolic hydroxyl and removal of 3-acetyl, then respectively esterifying with acetylated caffeic acid or coumaric acid acyl chloride, and removing a protecting group. The preparation method of the four catechins is simple and mild inconditions, and can be completed under general experimental conditions. The four hydroxycinnamyl ester type catechins have a certain inhibition effect on the activity of alpha-glucosidase, can be usedfor hypoglycemic drugs, and have important significance in the fields of agriculture and medicine.

catechin compounds and uses thereof

The present invention relates to catechin compounds or pharmaceutically acceptable salts thereof and uses thereof. The composition comprising the catechin compounds or pharmaceutically acceptable salts thereof, of the present invention, is very effective for antioxidant, anti-inflammatory activity and the treatment of wound.(AA) Control groupCOPYRIGHT KIPO 2019

Syntheses of doubly linked proanthocyanidins using free flavan units as nucleophiles: Insight into the origin of the high regioselectivity of annulation

A synthesis method of doubly linked flavan dimers is reported via the acid-promoted annulation reaction using nascent catechins, (+)-catechin or (-)-epicatechin, as a dianionic partner and an ethylenedioxy-bridged flavan as a dicationic partner. Procyanidins A1 and A2 were synthesized. On the high regioselectivity of the annulation reactions, model experiments and computational studies were carried out.

Development of a new synthetic strategy for procyanidin dimer condensation using peracetylated electrophiles

Proanthocyanidins, also known as condensed tannins and/or oligomeric flavonoids, are found in many edible plants and show interesting various biological activities. We report a simple new proanthocyanidin synthesis strategy in which an electrophile derived from a flavan-3-ol peracetate is condensed with 1.5 eq. of a benzylated nucleophile. We demonstrate here the synthesis of procyanidin B1, a (-)-epicatechin-(4β-8)-(+)-catechin dimer, to demonstrate the utility of this method. This strategy is applicable for the synthesis of various commercially available flavan-3-ol and various oligomeric flavonoids.

Isolation of arginase inhibitors from the bioactivity-guided fractionation of Byrsonima coccolobifolia leaves and stems

Byrsonima coccolobifolia leaf and stem extracts were studied in the search for possible leishmanicidal compounds using arginase (ARG) from Leishmania amazonensis as a molecular target. Flavonoids 1b, 1e-1g, 2a, 2b, and 2d-2f showed significant inhibitory

FLAVONOID COMPOUNDS

The present invention relates to compounds, compositions, and methods for treatment of conditions related to mitochondrial function. In various aspects, the present invention comprises administering one or more epicatechin derivatives in an amount effective to stimulate mitochondrial function in cells. The compounds, compositions, and methods described herein provide for reducing infarct size in the heart following permanent ischemia or ischemia/reperfusion event or method for delaying, attenuating or preventing adverse cardiac remodeling, and can assist in prevention of impaired mitochondria biogenesis and thus prevention of the consequences of impaired mitochondrial biogenesis in various diseases and conditions, as well as provide for the active therapy of mitochondrial depletion that may have already occurred.